Blue Fin Group presents a market study on the current and future management of oncology payers

NEW YORK, July 6, 2022 /PRNewswire/ — Blue Fin Group, a full-service management consulting firm for the pharmaceutical industry, today announced a new market research video assess current and future management of oncology payers by Kerri Fortier, Senior Consultant, and Jonny ClarkPharmD, Consultant (biographies are available here). Quantitative and qualitative data include influences on the payer’s decision to prefer oncology drugs, key barriers and influencers to managing oncolytics, and expectations for oncology management over the next three years, including the increase in preference contracts and value-based contracts. The study is based on an award-winning poster titled “Payers’ Perceptions and Practices Regarding Oncology Therapy Management” presented at AMCP Nexus at October 2021. The authors are available to the media for interviews.

About Blue Fin Group, an IntegriChain Company
Blue Fin Group develops strategies to optimize patient access, commercialization and gross/net ratio to support life science manufacturers throughout the product life cycle. Blue Fin Group is a full-service management consulting firm that provides research, strategy and implementation services to help manufacturers align all elements of marketing, market access, sales to the field, pharmacy and distribution and patient services as part of a transparent business strategy that helps optimize the patient. results. Blue Fin Group has served more than 300 manufacturers, mainly first-to-market or large global companies with products spanning cell and gene therapies, orphan/rare therapies, specialties, primary care, vaccines, biosimilars and generics. For more information, visit or follow Twitter and LinkedIn.

For media inquiries: Contact Cynthia Keviny at [email protected]

SOURCE Blue Fin Group, an IntegriChain company

Paul N. Strickland